



January 12, 2026

To,  
The Chief Manager, Surveillance  
**National Stock Exchange of India Limited**  
"Exchange Plaza", Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**SYMBOL: AARTIPHARM**

**Sub: Reply to clarification sought with respect  
to increase in the volume of security across the  
Exchanges**

**Ref.No.: NSE/CM/Surveillance/16325 dated  
January 09, 2026**

---

Dear Sir/Madam,

In reference to your email dated January 09, 2026, received at 06:17 p.m., regarding the significant increase in the trading volume of the Company's securities across the Exchanges in the recent past, we wish to clarify that the Company has been promptly disseminating to the Stock Exchanges all information and events required to be disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We further clarify that, other than the information already disclosed to the Stock Exchanges, there is no information or announcement (including any pending announcement) which, in our opinion, may have a bearing on the price or volume behaviour of the Company's scrip.

Therefore, the increase / movement in volume is absolutely market driven.

We hope the above clarifies and kindly take the same on record.

Thanking you,  
Yours faithfully,  
**For AARTI PHARMALABS LIMITED**

**JEEVAN MONDKAR**  
**COMPANY SECRETARY AND LEGAL HEAD**  
**ICSI M. NO. A22565**